CLSA Remains Positive on China's Biopharmaceutical Sector, Prefers INNOVENT BIO and SKB BIOAASTOCKS News·Nov 18, 2026 at 07:58 AM01801-2.68%
Innovent Biologics (IVBXF) Receives a Buy from Huatai SecuritiesTip Ranks·Nov 18, 2026 at 05:05 AM01801-2.68%
Innovent Says Takeda Wins Japan SAKIGAKE Designation for Gastric Cancer Drug Arcotatug TavatecanPUBT·Nov 17, 2026 at 08:30 AMTAK+0.23%01801-2.68%
UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO Ophthalmology R&DAASTOCKS News·Nov 17, 2026 at 05:27 AMJNJ-1.36%01801-2.68%
Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & JohnsonTip Ranks·Nov 16, 2026 at 02:40 PMJNJ-1.36%01801-2.68%
China Adds Record 51 Innovative Drugs to Public Medical Insurance CatalogYicai·Nov 16, 2026 at 11:44 AMAZN-0.95%NVO-2.16%
Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer TreatmentPUBT·Nov 15, 2026 at 11:46 PM01801-2.68%
Weekly Recap | INNOVENT BIO -1.97%, seven products join NRDLWeekly Review·Nov 14, 2026 at 05:12 AM01801-2.68%
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug Listprnewswire·Nov 14, 2026 at 03:51 AM01801-2.68%
Innovent Reports Preclinical Data Showing IAR177 Outperforms Single-Target Blockade in Rheumatoid Arthritis ModelsPUBT·Nov 13, 2026 at 12:00 AM01801-2.68%
SPRO: SP001’s IgG4-RD phase II is planned for Q2 2027, with funding runway into H2 2029Quartr·Nov 10, 2026 at 05:19 PMSPRO-4.77%01801-2.68%
Innovent's Sintbilo Meets Primary Endpoint in Phase 3 Cholesterol TrialPUBT·Nov 9, 2026 at 12:00 AM01801-2.68%
Weekly Recap | INNOVENT BIO +7.07%, most brokers rate it buyWeekly Review·Nov 7, 2026 at 05:38 AM01801-2.68%